Dry powder aerosol delivery systems: current and future research directions
- PMID: 16551211
- DOI: 10.1089/jam.2006.19.21
Dry powder aerosol delivery systems: current and future research directions
Abstract
Development of dry powder aerosol delivery system involves powder production, formulation, dispersion, delivery, and deposition of the powder aerosol in the airways. Insufficiency of conventional powder production by crystallization and milling has led to development of alternative techniques. Over the last decade, performance of powder formulations has been improved significantly through the use of engineered drug particles and excipient systems which are (i) of low aerodynamic diameters (being porous or of low particle density), and/or (ii) less cohesive and adhesive (via corrugated surfaces, low bulk density, reduced surface energy and particle interaction, hydrophobic additives, and fine carrier particles). Early insights into particle forces and surface energy that help explain the improvement have been provided by analytical techniques such as the atomic force microscopy (AFM) and inverse gas chromatography (IGC). Relative humidity is critical to the performance of dry powder inhaler (DPI) products via capillary force and electrostatic interaction. Electrostatic charge of different particle size fractions of an aerosol can now be measured using a modified electrical low-pressure impactor (ELPI). Compared with powders, much less work has been done on the inhaler devices at the fundamental level. Most recently, computational fluid dynamics has been applied to understand how the inhaler design (such as mouthpiece, grid structure, air inlet) affects powder dispersion. The USP throat is known to under-represent the oropharyngeal deposition of DPI aerosols. Studies using magnetic resonance imaging (MRI) model casts have been undertaken to explain the inter- and intra- subject variation in oropharyngeal deposition. Most of the lung deposition studies performed on commercial products did not allow a thorough understanding of the determinants affecting in vivo lung deposition. A more systematic approach would be necessary to build a useful database on the dependence of lung deposition on the breathing parameters, inhaler design, and powder formulation properties.
Similar articles
-
Development of dry powder inhalers.Recent Pat Drug Deliv Formul. 2007;1(1):11-21. doi: 10.2174/187221107779814159. Recent Pat Drug Deliv Formul. 2007. PMID: 19075871 Review.
-
Influence of humidity on the electrostatic charge and aerosol performance of dry powder inhaler carrier based systems.Pharm Res. 2007 May;24(5):963-70. doi: 10.1007/s11095-006-9218-8. Epub 2007 Mar 22. Pharm Res. 2007. PMID: 17377746
-
Computationally efficient analysis of particle transport and deposition in a human whole-lung-airway model. Part II: Dry powder inhaler application.Comput Biol Med. 2017 May 1;84:247-253. doi: 10.1016/j.compbiomed.2016.10.025. Epub 2016 Nov 3. Comput Biol Med. 2017. PMID: 27836120
-
Dry powder inhaler formulation.Respir Care. 2005 Sep;50(9):1209-27. Respir Care. 2005. PMID: 16122404 Review.
-
Air classifier technology (ACT) in dry powder inhalation Part 4. Performance of air classifier technology in the Novolizer multi-dose dry powder inhaler.Int J Pharm. 2006 Mar 9;310(1-2):81-9. doi: 10.1016/j.ijpharm.2005.11.029. Epub 2006 Jan 25. Int J Pharm. 2006. PMID: 16442246
Cited by
-
Preparation, characterization, and pharmacodynamics of insulin-loaded fumaryl diketopiperazine microparticle dry powder inhalation.Drug Deliv. 2019 Dec;26(1):650-660. doi: 10.1080/10717544.2019.1631408. Drug Deliv. 2019. PMID: 31257946 Free PMC article.
-
Development of a high efficiency dry powder inhaler: effects of capsule chamber design and inhaler surface modifications.Pharm Res. 2014 Feb;31(2):360-72. doi: 10.1007/s11095-013-1165-6. Epub 2013 Aug 16. Pharm Res. 2014. PMID: 23949304 Free PMC article.
-
Are inhaled systemic therapies a viable option for the treatment of the elderly patient?Drugs Aging. 2008;25(2):89-94. doi: 10.2165/00002512-200825020-00001. Drugs Aging. 2008. PMID: 18257596 Review.
-
Advancements in the Design and Development of Dry Powder Inhalers and Potential Implications for Generic Development.Pharmaceutics. 2022 Nov 17;14(11):2495. doi: 10.3390/pharmaceutics14112495. Pharmaceutics. 2022. PMID: 36432683 Free PMC article. Review.
-
Aerodynamic factors responsible for the deaggregation of carrier-free drug powders to form micrometer and submicrometer aerosols.Pharm Res. 2013 Jun;30(6):1608-27. doi: 10.1007/s11095-013-1001-z. Epub 2013 Mar 8. Pharm Res. 2013. PMID: 23471640 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous